Palvella Therapeutics PVLA Cash Acquired From Reverse Merger Transaction
Cash Acquired From Reverse Merger Transaction at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept pvla:CashAcquiredFromReverseMergerTransaction.
The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's cash acquired from reverse merger transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Palvella Therapeutics's cash acquired from reverse merger transaction?
- Palvella Therapeutics (PVLA) reported cash acquired from reverse merger transaction of $0 in Q4 2025.
- How has Palvella Therapeutics's cash acquired from reverse merger transaction changed year-over-year?
- Palvella Therapeutics's cash acquired from reverse merger transaction decreased by 100.0% year-over-year, from $3.45M to $0.
- What does cash acquired from reverse merger transaction mean?
- Represents the cash balance obtained by the company as a result of a reverse merger or reverse recapitalization transaction. This metric highlights the immediate liquidity infusion provided by the transaction structure. It is a critical data point for assessing the initial capital position of a company following a public listing via merger.